Baolingbao released its 2026 interim report. The company's total operating revenue was 1.496 billion yuan, and net profit attributable to the parent was 82.3211 million yuan, a decrease of 10.3509 million yuan from the same period last year, down 11.17% year-on-year. Net cash inflow from operating activities was 119 million yuan, the asset-liability ratio was 23.07%, the gross margin was 14.65%, and diluted earnings per share was 0.22 yuan, down 12.00% year-on-year. The number of shareholders was 27,300, and the top ten shareholders held 36.72% of the total share capital.
Baolingbao Biology Co LtdNet profit fell 11.17% year-on-year, with EPS down 12%.
